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1. Introduction 
Parkinson’s disease (PD) is a progressive disorder with a relentless neuronal cell loss in 
several brain areas and nuclei notably in the substantia nigra (SN). The course of this 
neuronal loss is still unclear and may be highly variable in different PD patients and at 
different phases of the disease. 
At present, no treatment has proven to influence this progressive course of the disease by 
protecting neurons or by postponing cell death. 
One potential reason for the lack of neuroprotective effects of various agents, which have 
been highly effective in animal experiments, is the fact that the neurodegenerative process 
has already substantially proceeded when the diagnosis is established on the basis of widely 
accepted diagnostic criteria for PD: when the patients fulfill the clinical criteria of PD, 60–
70% of neurons of the SN are degenerated and the striatal dopamine content is reduced by 
80%, suggesting that the remaining neurons of the SN are also altered.  
The “preclinical” phase may give the incorrect impression of patients exhibiting no clinical 
signs or symptoms of the incipient disease. Conversely, it is known that motor signs 
develop insidiously and minor signs of asymmetric hypokinesia may be detected years 
before the diagnosis of PD can be established. In addition, non-motor symptoms such as 
mood disorders, olfactorial, vegetative, sensory or neuropsychological signs may be noticed 
by the patients or physicians in advance of motor signs reflecting the dysfunction of 
dopaminergic or non-dopaminergic neurons. 
Therefore, the term “early” or “prediagnostic” phase of PD would more appropriately 
characterize this stage of the disease. The clinical impression of autonomic, olfactorial and 
affective symptoms preceding motor signs of PD are in line with the findings demonstrating 
that neuronal alteration, with regard to Lewy body formation, occurs first in the dorsal 
vagal nucleus, the olfactory bulb, the raphe and coeruleus nuclei before entering the SN. 
According to neuropathological findings, it is suggested that approximately 10% of subjects 
older than 60 years are in the “prediagnostic” phase of PD. These subjects exhibit the 
pathological hallmarks of PD, like Lewy bodies and neuronal loss at the SN, without 
showing the motor signs during life time that allow the diagnosis of PD. In only 10% of this 
group with so-called “incidental Lewy body disease”, neuronal loss will proceed reaching 
the degree where motor symptoms are distinct enough to allow the diagnosis of PD.  
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It would be of great interest with respect to research and treatment to identify those subjects 
at risk i) to initiate neuroprotective treatment earlier, giving them a better base to act and ii) 
to define the causes of more rapid neuronal loss and disease progression in those patients 
with “incidental Lewy body disease” who will cross the threshold of critical neuronal loss at 
the SN and develop PD. 
The duration of the early or prediagnostic period remains unknown. The duration of this 
phase of PD was estimated to last from a few years up to several decades before the first 
symptoms are noticed by the patients. 
Several procedures have been proposed to identify subjects in early (“prediagnostic”) stages 
of PD. In the following we present some instrumental approaches to identify patients in the 
early stages of PD. 
One set of simple behavioural tasks that may provide insight into the neural control of 
response suppression uses saccadic eye movements to investigate and quantify motor 
impairments in PD. The study of ocular movements has been increasingly used to detect 
subtle pathological modifications, caused by a wide variety of neurological diseases.  
A recent method, a new vision-based, nonintrusive, eye tracker, previously described in de 
novo PD patients (Marino et al., 2007), was proposed as a possible tool for supporting the 
diagnosis of PD in association with levodopa test, as an add-on to the Unified Parkinson 
Disease Rating Scale (UPDRS) score (Marino et al., 2010). 
In addition, conventional MR Imaging (cMRI), as well as different advanced MRI 
techniques, including magnetic resonance spectroscopy (MRS), magnetization transfer 
imaging (MTI), diffusion-weighted and diffusion tensor imaging (DWI/DTI) are helpful to 
distinguish PD from atypical or secondary PD, especially in early stage of disease where a 
differentiation of these conditions is not easy. 
Objective olfaction tests, such as olfactory-evocated potentials or functional magnetic 
resonance imaging, can be used to assess the severity of olfactory dysfunction, an early 
clinical feature of PD, its correlation with cerebral changes, and then the risk of developing 
PD in asymptomatic subjects. 
2. Analysis of pursuit ocular movements in Parkinson’s disease by using a 
video-based eye tracking system 
Patients with PD characteristically have difficulty initiating movements (akinesia). When 
movements are initiated, they are of low velocity (bradykinesia) and reduced amplitude 
(hypokinesia). In addition, patients with PD are unable to sustain repetitive motor action. 
When they attempt to open or close the hand rapidly or tap the foot on the ground, the 
movement rapidly decreases in amplitude and slows in speed until it ceases. This disability 
is easily appreciated in the progressive micrographia of the handwriting of PD patients. 
Research in the past 30 years has established that PD impairs control of eye movements. 
Voluntary saccades, such as self-paced, predictive and remembered saccades, are 
hypometric, multistep, of reduced velocity and of increased duration. Visually guided 
saccades are normal. Advanced PD is known to be associated with reduced ocular smooth 
pursuit gain (Bares et al., 2003; Lekwuwa et al., 1999). This has been explained in terms of 
advanced PD affecting other structures outside the basal ganglia.  
A recent study (Marino et al., 2007) described a new eye movement measurement and 
analysis system which was developed for generating a set of visual stimuli paradigms and 
which is able to measure, analyze and record the resulting horizontal eye movements.  
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Oculomotor movements are controlled by many brain areas including the cerebral cortex, 
basal ganglia, brain stem and cerebellum. PD is a condition of degeneration of dopaminergic 
neurons in the substantia nigra pars compacta, resulting in progressive basal ganglia 
dysfunction. Because important eye movement pathways travel through the basal ganglia, 
aspects of oculomotor movement control should be impaired by the disease progression. 
This study showed that deficit in Pursuit Ocular Movements (POM) also occurs in patients 
with non-advanced PD and is closely correlated with clinical stage and motor scores.  
The authors used a vision-based non-intrusive eye tracker. The developed interface provides 
the patients a visual stimulation. This system was able to measure, analyze and record the 
resulting horizontal eye movements.  
The subjects were seated at 60 cm from the scene monitor, in front of the camera, on a chair 
which could be raised or lowered so that the subject’s eyes were at the same height as the 
PC monitor, when the visual stimulus was administered on. The subjects were asked to 
perform the test three times. 
 
 
Fig. 1. Video-based eye-tracking functional scheme: subject looks at the screen (laptop or 
desktop PC) and all mechanical and electronic supports help to perform a real-time 
acquisition of eye movements.  
The results of the study confirm that POM are clearly impaired in patients with de novo PD. 
The same authors (Marino el al., 2010) studied the POM by using the same vision-based 
non-intrusive eye tracker, in patients with suspected PD, before and after L-Dopa 
administration. 
All patients had a positive test demonstrated by the improvement of UPDRS motor 
subscore, after L-Dopa administration, and as a new finding, by the improvement of POM. 
A plausible explanation is that the improvement of horizontal eye displacement gain was 
induced by the dopaminergic action of L-Dopa. Some newly diagnosed PD patients have 
been shown to improve POM after L-Dopa treatment and this suggested the possibility of 
dopaminergic control of ocular movements, particularly smooth pursuit and saccades.  
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The POM methodology could be considered as a not invasive, objective and repetitive 
method (and these conditions could be an advantage with respect to only UPDRS 
examination) to support the clinical evaluation. 
This method could be considered as a possible tool for supporting the diagnosis of PD in 
association with levodopa test, as an add-on to the UPDRS score. These results showed that 
this vision-based eye tracker can be used as reliable indices of disease severity in early and 
suspected PD patients. 
3. Diagnosis of Parkinson’s disease by using MR techniques 
PD in its early stages can easily be mistaken for any number of disorders. Indeed PD is most 
likely to be confused with various Atypical Parkinsonian Disorders (APDs) such as 
Progressive Supranuclear Palsy (PSP), Multiple-System Atrophy (MSA), especially the 
Parkinson variant of MSA (MSA-P), and Corticobasal Degeneration (CBD). 
A differentiation of these clinical entities, each characterized by completely different natural 
histories, may be challenging, particularly in the early stages of the disease, where 
overlapping clinical signs lead to a high rate of misclassification. However, a differentiation 
between APDs and PD, that may make easier early diagnosis, is crucial for determining the 
prognosis and choosing a treatment strategy.  
Magnetic Resonance Imaging (MRI) plays an important role in the differential diagnosis in 
PD. Conventional MRI (cMRI) and advanced MRI techniques, including proton magnetic 
resonance spectroscopy, diffusion-weighted and diffusion tensor imaging and 
magnetization transfer imaging, are helpful to distinguish PD from atypical or secondary 
PD. 
3.1 Magnetic Resonance Spectroscopy 
MRS is a non-invasive technique that can be used to measure the concentrations of different 
low-molecular weight chemicals. The technique is based on the same physical principles as 
MRI, i.e. the detection of energy exchanges between external magnetic fields and specific 
nuclei within atoms. MRS is the more modern version of Nuclear Magnetic Resonance 
which over the past five decades has evolved from a technique used in chemistry to 
determine the structure of molecules to a method with which to probe the metabolism of 
cells, tissues, intact animals and humans (Allen, 1990; Avison et al., 1986).  
MRS has been demonstrated in vivo for different nuclei, including 1H, 31P, 13C, 15N, 19F and 
23Na. While most of these nuclei are very difficult to detect, 1H and 31P are available in the 
human brain in significant concentration and have the appropriate physical configuration to 
be detected by MRS. For instance, 31P-MRS has been the first to be applied to medicine in 
vivo, and can be used to evaluate brain energy metabolism by directly and non-invasively 
measuring of Adenosine Triphosphate (ATP), Phosphocreatine (PCr) or Inorganic 
Phosphate (Pi) concentrations. While 31P-MRS was the first spectroscopic technique to be 
applied in vivo, the main nucleus studied today in neurospectroscopy is 1H, which provides 
information on markers of neurons, myelin, energy metabolism and other metabolically 
active compounds. 
1H-MRS detects very small differences in the frequencies of proton resonances from 
comparatively large volumes (1 ml or more) of brain tissue. The frequency of the resonance 
is affected by its local chemical environment, while the amplitude reflects its concentration. 
As such, 1H-MRS is able to provide a measurement of certain proton-containing chemical 
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markers. Proton spectroscopy presents the problem that metabolites at millimolar 
concentration must be detected in the presence of a background water signal that is present 
at about 100 molar. For this reason solvent-suppression techniques have been combined 
with localization schemes to produce spatially localized solvent-suppressed spectra. The 
two most commonly used localization methods are STEAM and PRESS. These methods can 
be implemented as single-voxel and multi-voxels methods. With the single voxel 
localization, the signal is acquired from a single brick-shaped volume of various sizes 
(minimum volume 2-3 cm3). The multi-voxel or MR spectroscopic imaging (MRSI) or 
Chemical Shift Imaging (CSI) approach generates individual spectra from multiple voxels at 
the same time (minimum volume 0.5-1 cm3). Single-voxel spectroscopy detects the signal 
from a single region during one measurement, whereas MRS imaging, using additional 
phase-encoding pulses, obtains the signal from multiple regions at the same time and 
provides the information of spatial distribution of major cerebral metabolites. The spatial 
information in MRI is done in 2-D for one or more slices and can generate low-resolution 
images for each metabolite by integration of the MR signals from each voxel (Ross & Bluml, 
2001). The possibility to acquire the spectra from 2D multi-voxel allows to study the 
metabolite distribution of a large area of the brain with the advantage of identifying more 
anatomical and functional details. Most importantly, collecting data from many different 
adjacent regions simultaneously reduces the potential for systemic errors that can affect 
sequential measurements and thus results in more accurate repeated studies. 
The metabolites detectable with 1H-MRS include the prominent resonances of N-
acetylaspartate (NAA), choline-containing compounds (Cho), creatine + phosphocreatine 
(Cr), myo-inositol (mI), lactate (Lac), and a variety of other resonances that might not be 
evident depending on type and quality of spectra as well as on the pathological condition 
(Figure 2) (Bonavita et al., 1999; Lin et al., 2005). 
NAA, which resonates at 2.02 parts per million (ppm), represents the largest proton 
metabolic concentration in the human brain after water. Indeed the concentration of NAA 
reaches on the order of 10 μmol/g. NAA is widely interpreted as a neuronal marker and 
implicated in several neuronal processes, mitochondrial functioning and osmoregulation. 
NAA synthesis occurs in mitochondria and requires acetyl-CoA and L-aspartic acid as 
substrates. NAA has been proposed to serve as a mitochondrial shuttle of acetyl-CoA used 
for fatty acid synthesis. NAA undergoes dramatic increase during brain development and 
significant decrease during lesion progression in various neurodegenerative diseases, 
suggesting an important, unknown role in brain metabolism (Clark, 1998).  
The Cho peak (3.2 ppm) represents a combination of several choline-containing compounds, 
including free Cho, phosphorylcholine and glycerophosphorylcholine, and to a small extent 
acetylcholine. Free Cho acts as a precursor to acetylcholine, while glycerophosphorylcholine 
is a product of breakdown of membrane phosphatidylcholine and acts as an osmoregulator.  
The concentration of Cho is relatively low on the order of 0.5 to 1.5 μmol/g and can be 
altered in normal aging and many focal inflammatory diseases. The Cho peak is often 
viewed as a marker of membrane turnover or inflammation in 1H MRS studies. 
The concentration of total Cr is estimated on the order of 8 to 9 μmol/g and is 
approximately 20% higher in human gray matter than white matter. In 1H-MRS, the 
resonance at 3.03 ppm represents total Cr and PCr supplies phosphate for conversion of 
ADP to ATP in creatine kinase reaction. Indeed these metabolites buffer the energy use and 
energy storage of cells. The level of total Cr mainly remains constant in many neuronal 
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Fig. 2. Chemical structure of main cerebral metabolites detected by 1H-MRS. 
diseases. Thus, total Cr is often used as an internal reference (i.e., a denominator in 
metabolite signal ratio). 
The mI (3.56 ppm) has been recognized as a cerebral osmolyte or an astrocyte marker due to 
its cellular specificity based on cell culture studies. mI is also been known as a breakdown 
product of myelin and precursor of inositol polyphosphate, an intracellular messenger. The 
concentration of mI is on the order of 5–10 μmol/g while one of its isomers, syllo-inositol, 
has substantially lower concentrations of on the order of less than 1 mol/g in the brain and 
remains relatively consistent in many diseases.  
The Lac (1.3 ppm) is an end product of anaerobic glycolysis, thus increase in Lac 
concentrations often serves as an index of altered oxidative metabolism, i.e., in ischemia, 
hypoxia, and cancer. The concentration of Lac is on the order of about 1 μmol/g in normal 
COO
NH
CO
CH
3
-OOC
-
N-Acetylaspartate (NAA)  
NH
2
NH
N
CH
3
COO
+
-
Creatine (Cre) 
CH
3
OH
COO
-
Lactate (Lac)
OH
OH
OH
OH
OH
OH
Myo-inositol (mI)    
OH
OH
O
P
O
O
O
-
N(CH
3
)
3
+
Choline - containing compounds (Cho) 
OH
N(CH
3
)
3
+
www.intechopen.com
 
Early Marker for the Diagnosis of Parkinson's Disease 
 
9 
aerobic conditions. Increases of Lac in the brain are often accompanied by decreased 
intracellular pH and high-energy phosphates. The proposed role of Lac is a source of energy 
for neurons and the transport of Lac plays an essential role in the concept of metabolic 
coupling between neurons and glia. 
The concentration changes of all metabolites detected by 1H-MRS and 31P-MRS could help to 
evaluate PD subjects in the “preclinical” stages, especially in early differential diagnosis. 
1H-MRS of striatal structures might differentiate PD from APDs by virtue of reduced 
NAA/Cr ratios in MSA but not PD. 1H-MRS showed reduced NAA/Cr ratios in the 
lentiform nucleus in six of seven MSA-P cases, whereas normal levels of putaminal NAA 
were found in eight of nine PD subjects (Davie et al., 1995). 
As compared to normal controls, in patients with PSP, CBD, and MSA, but not in those with 
PD, significant reduction of the NAA/Cr ratio in the frontal cortex was found (Abe et al., 
2009). Patients with CBD showed significant reduction of the NAA/Cr ratio in the frontal 
cortex and putamen as compared to patients with PD and MSA. Patients with PSP showed a 
significant reduction of the NAA/Cr ratio in the putamen as compared with patients with 
PD and MSA. Patients with CBD showed clear asymmetry in the putamen as compared to 
controls and other patients (Abe et al., 2009). By application of 1H-MRSI statistically 
significant difference in regional patterns of the NAA/Cr and NAA/Cho ratios between 
patients with PD and those with CBD and between patients with PD and those with PSP 
was found (Tedeschi et al., 1997). 
Other 1H-MRS examinations didn’t show significant difference between the PD patients and 
the control subjects (Tedeschi et al., 1997), also in the striatum (Holshouser et al., 1995), in 
the putamen and globus pallidus (Federico et al., 1997), and in occipital lobe (Bowen et al., 
1995). The NAA/Cho and NAA/Cr ratios were significantly reduced in the putamen and 
globus pallidus of MSA and the PSP patients, in which neuronal loss involves, compared 
with the control subjects (Federico et al., 1997). In another study Federico at al. showed that 
NAA/Cho peak ratio was significantly reduced in MSA and in PSP patients compared to 
PD patients and to control. Moreover the NAA/Cr peak ratio was significantly reduced in 
MSA, in PSP and in PD patients also compared to controls, but only in MSA compared to 
PD patients (Federico et al., 1999). 
Normal 1H-MRS data could suggest the clinical diagnosis of PD, whereas low striatal levels 
of NAA could suggest the diagnosis of MSA or PSP. 
However, further MRS studies have shown reduced NAA/Cr and NAA/Cho ratios in the 
lentiform nucleus not only in APD, but also in PD (Clarke & Lowry, 2001; Firbank et al., 
2002).  
Technical factors such as MRS technique including different echo- time and relaxation-time, 
voxel sizes, field strength and pulse sequences used in the different studies, may be 
responsible for some of the variation of results seen in the published literature on 1H-MRS 
for the differential diagnosis of neurodegenerative parkinsonism (Clarke & Lowry, 2001; 
Firbank et al., 2002). The development of 1H-MRS at higher magnetic field strengths may 
lead 1H-MRS to a more important role as imaging tool in the differential diagnosis of 
parkinsonian disorders. 
1H-MRS of the brain with high magnetic field at 3 Tesla has many advantages that, with 
respect to the well-established and technologically advanced 1.5 Tesla 1H-MRS, include 
better signal to noise ratio (SNR) and increased spectral, spatial and temporal resolution, 
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allowing the acquisition of high quality, easily quantifiable spectra in acceptable imaging 
times (Di Costanzo et al., 2007). 
The increase SNR associated with higher magnetic fields permits shorter imaging times for a 
given spatial resolution, higher resolution for a given imaging time or the combination of 
both.  
The spectral resolution is linearly correlated with the field strength and is about twice at 3 
Tesla as compared to 1.5 Tesla. Clinical 1.5 Tesla scanners equipped with 1H-MRS packages 
allow the quantification of NAA, Cho, Cr and lactate at long echo-time, and further 
metabolites, such as mI and glutamate-glutamine (Gxl), at short echo-time. mI is a strongly 
coupled system and resonates at four chemical shift positions. At 1.5 Tesla, only the singlet 
component at 3.57 ppm is detected. However, at 3 Tesla this resonance is resolved into its 
components at 3.55 and 3.61 ppm. Therefore by increasing of spectral resolution and SNR, 
the quantification precision of mI is significantly better at 3 Tesla relative to 1.5 Tesla 
(Srinivasan et al., 2004). 
Despite shorter T2 relaxation times and increased field inhomogeneity, the chemical shift 
doubling at 3 Tesla yields better spectral resolution. This is reflected by improved baseline 
separation of Cho and Cr, which are only 0.2 parts per million (ppm) apart, and by slightly 
better resolution of Glu/Gln region, between 2.05 and 2.5 ppm, at shorter TE.  
Higher field strengths also lead to a flatter baseline that contributes to more reliable 
estimation of peak area and, hence, more precise quantification, in addition to a more 
accurate identification of each metabolite.  
This has been shown by a recent study applying multiple regional single voxel 1H-MRS 
including putamen, pontine basis and cerebral white matter at 3 Tesla in 24 patients with 
MSA compared to 11 PD patients and 18 controls. Significant NAA/Cr reductions have 
been shown in the pontine basis of both patients with MSA-C (cerebellar ataxia variant of 
MSA) and MSA-P, while putaminal NAA/Cr was only reduced in the patients with MSA-P. 
Eight of the 11 MSA-P patients compared to none of the PD and control group were 
classified correctly by combining individual NAA/Cr reductions in the pontine basis and in 
the putamen. These results suggest that combined assessment of NAA/Cr in the pontine 
basis and putamen may be effective in differentiating MSA-P from PD in terms of the high 
specificity of reduced NAA/Cr in the pontine basis or in the putamen in patients with MSA-
P (Watanabe et al., 2004). 
Moreover, in these studies, the metabolite concentrations were expressed in terms of 
semiquantitative ratios such as NAA/Cr, NAA/Cho, Cho/Cr and mI/Cr. In relative 
quantification, one of the metabolite peaks measured is used as the concentration standard 
and serves as the denominator of the peak ratios. As a result, the total number of 
quantifiable metabolites is decreased by one. Furthermore, alterations in the peak ratio do 
not necessarily reflect a change in the concentration of the numerator. The alteration may be 
caused by change in the concentration of the numerator, the denominator, or both or may be 
due to changes in relaxation behavior. The assumption that the concentration of certain 
reference metabolites (e.g. total creatine, choline) remains constant may be incorrect under 
normal conditions, as well as in many pathologic states. It is therefore advisable to obtain 
concentration expressed in standard units (such as millimoles per kilogram wet weight) by 
applying absolute quantification. 
Combined 31P- and 1H-MRSI at 3 Tesla measuring absolute adenosine diphophosphate 
(ADP), ATP, Cr and PCr concentrations in two well-defined cohorts of patients with early 
and advanced PD has been performed to evaluate brain energy metabolism (Hattingen et 
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al., 2009). In the putamen and midbrain of both PD groups compared to control was found a 
bilateral reduction of high-energy phosphates such as ATP and PCr as final acceptors of 
energy from mitochondrial oxidative phosphorylation. In contrast, low-energy metabolites 
such as ADP and Pi were within normal ranges. Patients with early Parkinson’s Disease, 
with clearly lateralized motor symptoms, exhibited a significant reduction of putamen high-
energy phosphates in the less affected hemisphere with a less pronounced dopaminergic cell 
loss. Therefore, mitochondrial dysfunction is a rather early occurring and subsequently 
persistent event in the pathophysiology of dopaminergic degeneration in PD. These data 
strongly support the hypothesis that mitochondrial dysfunction is involved early in 
pathogenesis of PD and it may be used as early marker for this pathology. 
In vivo MRS is increasingly utilized for the study of neurochemistry and cerebral energy 
metabolism in PD. Particularly, the recent technical advances of in vivo MRS including the 
availability of higher magnetic fields permitting improved spectral and spatial resolution, 
the development of a reliable method for absolute metabolite quantification, the 
development of various spectroscopic methods to enhance metabolite signal identification, 
and the application of combined 31P- and 1H-MRS can be use to examine the changes in 
neurochemical profile non–invasively and to achieve a differential diagnosis of PD versus 
other forms of parkinsonism, especially in early stages of disease when signs and symptoms 
of different forms of parkinsonism have greater overlap. However, several  multicentre  
trials using a larger sample of patients, absolute quantification of tissue metabolite 
concentrations and a standardized technique are required to fully determine the place of 
MRS in early clinical differential diagnosis. 
3.2 Conventional Magnetic Resonance 
 In the early disease stages the clinical separation of atypical parkinsonism disorders (APD)s 
from PD carries a high rate of misdiagnosis. An early differentiation between APD and PD, 
each characterized by completely different natural histories, is crucial for determining the 
prognosis and choosing a treatment strategy.  
The principles of MR imaging are based on the ubiquitous presence of hydrogen in body 
tissues and the spin of the hydrogen atom proton, which induces a small magnetic field. In 
general, T2- weighted sequences are sensitive to changes in tissue properties, including 
tissue damage, due to changes of the transverse magnetization or T2 decay. 
Neurodegenerative processes characterized by cell loss, increased age-related deposition of 
iron or other paramagnetic substances, and by astroglial reaction and microglial 
proliferation may lead to signal changes in affected brain areas, like the basal ganglia or 
infratentorial structures, in neurodegenerative parkinsonism (Duguid et al., 1986; Gupta et 
al., 2008; Hirsch et al., 2007; Wilms et al., 2007). 
Because cMRI is believed to be usually normal in patients with PD, while it frequently 
shows characteristic abnormalities in patients with APD, cMRI images takes a major part in 
excluding underlying pathologies such as vascular lesions, multiple sclerosis, brain tumors, 
normal pressure hydrocephalus, bilateral striopallidodentate calcinosis, and other potential, 
but rare, causes of symptomatic parkinsonism such as Wilson disease, manganese-induced 
parkinsonism, or different subtypes of neurodegeneration associated with brain iron 
accumulation.  
At 1,5 T, patients with advanced PD, and sometimes those with APD, may show distinct 
abnormalities of the substantia nigra, including signal increase on T2-weighted MR images, 
smudging of the hypointensity in the substantia nigra towards the red nucleus or signal loss 
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when using inversion recovery MRI (Brooks, 2000; Rutledge et al., 1987; Savoiardo et al., 
1994). 
Biochemical studies have reported increased iron content in the substantia nigra pars 
compacta (SNc) in PD, with changes most marked in severe disease, suggesting that 
measurement of nigral iron content may provide an indication of the pathologic severity of 
the disease (Youdim et al.,1990). Iron accumulates in the brain as a function of age, primarily 
in the form of ferritin and particularly in oligodendrocytes, but also in neurons and 
microglia. The adult brain has a very high iron content, particularly in the basal ganglia. 
Brain iron concentration is highest in the globus pallidus, substantia nigra, red nucleus, 
caudate, and putamen. Abnormally elevated iron levels are evident in various 
neurodegenerative disorders, including PD where there is evidence of increased iron in the 
substantia nigra (Dexter et al.,1989; Sofic et al.,1988). Signal changes on T2-weighted images 
in the basal ganglia as well as in infratentorial structures have been reported for all APDs at 
1.5 T, where they have been used as a differentiating criterion from PD. Furthermore, 
estimation of transverse relaxation in patients with PD, using a 1.5 Tesla whole body 
imaging system, showed shortened T2 values in substantia nigra, caudate and putamen in 
PD patients as compared to healthy controls (Antinoni et al., 1993). These data do suggest a 
potential utility of these measurements as a biomarker of disease progression. 
3.3 Magnetization Transfer Imaging 
Standard MR imaging detects signal only from hydrogen nuclei (protons) that are ‘‘mobile’’ 
(contained within a liquid); if a hydrogen atom is part of a molecule that is large and cannot 
move about freely, the signal from that hydrogen atom decays too quickly to be seen using a 
clinical MR imaging scanner. Such protons are found in large molecules (macromolecules), 
such as those of cell membranes and myelin. The mobile protons are in constant motion, 
however, and come into regular and intimate contact with the macromolecular protons, and 
the spin state (the proton magnetization state, which is measured with MR imaging) of the 
mobile protons can exchange with that of the macromolecular protons. This exchange of 
magnetization forms the basis of magnetization transfer imaging (Horsfield, 2005). 
Magnetization transfer is a physical phenomenon that results from interactions and 
exchanges between magnetized protons in water that are unrestricted in their molecular 
motion and those that are restricted because of their association with macromolecules. The 
latter have a much shorter T2 relaxation time and broader resonance, which makes it 
possible to selectively saturate their magnetization with an appropriate off-resonance pulse. 
The acquisition of two images, one obtained with the magnetization transfer saturation 
pulse turned on and the other with it turned off, can be used to generate a magnetization 
transfer ratio (MTR) image in which the signal intensity of each voxel is determined by the 
percent magnetization transfer in that voxel. 
A MTR image is calculated from a pair of images acquired in an identical way, except that 
one has extra off-resonance RF pulses applied, which saturates the macromolecular 
magnetization pool. The MTR is calculated for every corresponding pair of pixels in the 
two images. If the intensity of the pixel in the image without saturation pulses is M0 and 
the corresponding intensity in the image with saturation pulses is Ms, the MTR is as 
follows: 
MTR= [(M0 - Ms)/M0]* 100% 
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Fig. 3. Diagrams illustrate magnetization transfer, that is, the exchange of longitudinal 
magnetization between restricted protons associated with rigid macromolecules and free 
water protons. (a)Diagram shows macromolecular protons (H), including hydration layer 
protons and free water protons. (b) Off-resonance irradiation (arrows) saturates the 
immobile macromolecular protons (unsatured protons are designated H, while satured are 
designated H). (c) Saturation is transferred to hydration layer protons (…H). (d) Satured 
protons diffuse into the free water proton pool and decrease the signal from this pool. 
Misregistration can occur if the subject moves between the two scans, but the M0 and Ms 
images must be in register; otherwise, artifacts appear at the edges of features in the 
calculated MTR image, with false MTR values. It is best to acquire the two images in an 
interleaved way (Barker et al., 1996; Inglese at al., 2001) although it is possible to register 
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them after acquisition. Two forms of data analysis have been used extensively for MTR 
images: region of interest (ROI) and histogram analysis. ROI analysis may be useful for 
elucidating the degree of tissue damage within individual lesions seen on T2-weighted 
scans or within anatomic regions associated with particular symptoms. ROI analysis, 
however, can be subject to operator bias, because the placement of regions is normally done 
manually. This could be overcome by first registering scans to an anatomic template and 
using ROIs defined on the template image. With MTR histogram analysis, a histogram of 
pixel MTR values is formed from the whole of the brain parenchyma; thus, focal damage 
and more widespread diffuse tissue damage are reflected in changes to the shape of the 
histogram, with a general shift toward lower MTR values as the density of macromolecules 
is reduced with demyelination or axonal loss. Extraction of the brain parenchyma, using the 
same procedures that are used in atrophy measurements, is a necessary preprocessing step. 
After normalization (to remove any effect of the absolute brain size), the MTR histogram can 
be characterized by several simple statistics, such as the histogram peak position, the peak 
height, and the average MTR. The employment of off-resonance irradiation was first 
proposed by Wolff and Balaban (Wolff & Balaban, 1989), who found that use of an off-
resonance radio-frequency preparation pulse could generate excellent tissue contrast in 
images of rabbit kidney, and they referred to the technique as “magnetization transfer 
contrast.” The initial magnetization transfer occurs between the macro-molecular protons 
and the transiently hound hydration layer protons. The efficiency of this interaction is 
directly related to the number of irradiation sites (hydrogen bonds) and their mobility. The 
utilization of magnetization transfer was extended to clinical imaging, including its use with 
gradient-echo imaging and MR angiography (Wolff et al.,1991; Pike et al., 1992). A decrease 
in the MTR, which reflects a reduction in the exchange of magnetization of protons that are 
tumbling freely and those that are bound to macromolecules, is evidence of demyelination 
in cerebral white matter. MTR imaging is sensitive to both microscopic and macroscopic 
pathology and provides quantitative data on the extent of myelin loss in MS.  
By using MTI, abnormalities of the basal ganglia and SN have been reported in patients with 
PD, MSA and PSP. One study (Eckert et al., 2004)  investigated the potential of MT imaging in 
the differential diagnosis of neurodegenerative parkinsonism, including 37 patients with 
different parkinsonian syndromes and 20 age-matched controls. The main finding in this study 
was a change in the MTR in the globus pallidus, putamen, caudate nucleus, SN, and white 
matter in PD, MSA, and PSP patients, matching the pathologic features of the underlying 
disorder. MTR were significantly reduced in the putamen in MSA patients compared with PD 
patients and healthy controls, as well as in the SN in patients with PSP, MSA, and PD. Another 
study (Yonca et al., 2007) determinated the role of MTR in the early period of 33 patients with 
PD, comparing the findings with those in 30 normal healthy volunteers. Signal intensity 
measurements were obtained from 15 anatomic regions: SNc, substantia nigra pars reticulate 
(SNPR), red nucleus, dentate nucleus, cerebellum, pons, globus pallidus, putamen, caudate 
nucleus, thalamus, internal capsule posterior horn, forceps major, forceps minor, genu, and 
splenium of corpus callosum. Results showed a significant decrease of MTR in the SNc, SNPR, 
red nucleus, and pons compared with normal healthy volunteers. No significant decrease in 
MTR were found at supratentorial paraventricular white matter and cerebellum, which may 
be attributed the duration of the disease.  
Perhaps in the initial stages of PD, supratentorial paraventricular white matter is not 
influenced by the disease. The decrease of MTR at SNc, SNPR, red nucleus, and pons in PD 
patients can be attributed to neurodegeneration (Tambasco et al., 2003)). 
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These studies show that MTR analysis may be a useful technique for PD diagnosis and 
decrease in MTR probably begins previously than the clinical onset of the disease.  
3.4 Diffusion-Weighted Imaging 
DWI imaging visualizes the random movement of water molecules in the tissue by applying 
diffusion-sensitizing gradients to assess changes in diffusion magnitude and orientation of 
water molecules in tissue. Quantification of the diffusivity is achieved by applying 
diffusion-sensitizing gradients of different degrees in 3 orthogonal directions and 
calculating the apparent diffusion coefficient (ADC) for each direction. The ADC is very 
dependent on the direction of diffusion encoding.  
 
 
Fig. 4. Image-based visualization of diffusion tensor data. Top: Sphere representing 
directional color encoding. Second row: 2D images of image based visualization (from left: 
FA image, mean diffusivity image, and color-encoded image).  
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The random translational motion (diffusion) of water molecules in tissue is restricted by the 
highly organized architecture of fiber tracts in the central nervous system. Neuronal loss 
and gliosis disrupt this architecture, resulting in an increase of diffusivity and ADC. The 
complex neuronal architecture with its organization in fiber bundles that are surrounded by 
dense myelin sheaths leads also to a distinct anisotropy of water diffusion, which is 
facilitated along the direction of fiber tracts and restricted perpendicular to the fibers.  
The degree of anisotropy can be quantified by applying diffusion-sensitizing gradients in at 
least 6 directions, which permits calculation of fractional anisotropy (FA). Decreased FA 
values represent tissue degeneration due to normal aging or due to pathologic reasons such 
as neurodegeneration. Both diffusivity and FA can be combined to form the so-called 
diffusion tensor, which indicates direction and extent of diffusivity with the help of a vector 
(Hagmann et al., 2006; Le Bihan, 2003; Schocke et al., 2004). The central nervous system 
(CNS) is highly organized in numerous tracts of myelinated fibre bundles, whereby the 
movement of the water molecules is restricted perpendicular to these fibre bundles. The 
resulting anisotropic diffusion is quantified by the FA, which is determined by diffusion-
sensitised gradients in at least six directions. Both the diffusivity and the FA form the 
diffusion tensor (Le Bihan, 2003).  
Widespread cerebral changes are observed in advanced stages of PD, suggesting that PD is a 
multisystem disorder. 
Recently, several studies pointed out the capability of the histogram analysis of the apparent 
diffusion coefficient computed from diffusion-weighted images and of the mean diffusivity 
and FA computed from DTI to reveal brain-tissue damage in early clinical stages of 
neurodegenerative diseases. A recent study including 27 patients with de novo drug-naïve 
PD hypothesized that global measurements of brain volume and structure, such those 
possible with SIENAX software (part of FSL 4.0 http://www.fmrib.ox.ac.uk/fsl/) and 
histogram analysis of DTI could reveal subtle tissue changes in the early clinical phase of PD 
(Tessa et al., 2008). Accordingly, a group of patients with drug-naive de novo PD and a 
group of 16 healthy controls, were investigated with SIENAX and DTI. Results showed no 
significant differences for total brain, GM, and WM volumes and histogram-derived mean 
diffusivity metrics between controls and the whole group of patients with PD or any 
subgroup of patients with PD. As compared with controls, patients with PD as a whole and 
patients with the akinetic-rigid type showed an increase of the twenty-fifth percentile of the 
FA histogram. In patients with the akinetic-rigid type, there also was a trend toward an 
increase of the mean and fiftieth and seventy-fifth percentiles, and a reduction of the 
skewness of the FA histogram. This finding is consistent with the hypothesis that subtle GM 
loss is present in patients with PD since the early clinical phases and that this feature is more 
pronounced in patients with akinetic-rigid type. Another recent study including only 
patients with newly diagnosed PD used high-resolution DTI at 3 Tesla to evaluate rostral, 
middle, and caudal ROIs within the SN on a single slice of the midbrain and this study 
found that PD patients could be completely separated from the control group based on 
reduced FA values in the caudal ROI of the SN, such that further confirmatory studies seem 
to warrant. By using statistical parametric mapping analysis of DT imaging, changes in FA 
were found in the frontal lobes, including the supplementary motor area, the 
presupplementary motor area, and the cingulum in non demented PD patients relative to 
controls, whereas VBM analysis in the same patients revealed no volume loss (Karagulle 
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Kendi et al., 2008). These results confirm that the neurodegenerative process extends beyond 
the basal ganglia in PD (Tessa et al., 2008). 
Olfactory impairment, which is common in PD and often predates clinical diagnosis, may be 
a useful biomarker for early PD. One study (Rolheiser et al., 2011)  compared newly 
diagnosed PD patients with a matched control group using both olfactory testing and 
diffusion tensor imaging of the substantia nigra and anterior olfactory structures. Fourteen 
PD patients with stage 1-2 of Hoehn & Yahr were matched to a control group by age and 
sex. All subjects  completed the University of Pennsylvania Smell Identification Test, as well 
as a series of MRI scans designed to examine diffusion characteristics of the olfactory tract 
and the substantia nigra. Olfactory testing revealed significant impairment in the patient 
group. Diffusion tensor imaging revealed significant group differences in both the 
substantia nigra and anterior olfactory region, with fractional anisotropy of the olfactory 
region clearly distinguishing the Parkinson's subjects from controls. This study has 
suggested that there may be value in combining behavioral (olfaction) and MRI testing to 
identify early Parkinson's disease (Rolheiser et al., 2011; Fulton & Barret, 2008). 
Concluding DWI/DTI imaging especially bears several advantages. DWI/DTI imaging may 
detect diffusion abnormalities in the basal ganglia and infratentorial structures in patients 
with PD at an early stage of disease. Furthermore, DWI/DTI imaging sequences are widely 
available on whole body MR scanners and can be acquired within a few minutes. 
3.5 Functional Magnetic Resonance Imaging  
fMRI is based on the increase in blood flow to the local vasculature that accompanies neural 
activity in the brain. This results in a corresponding local reduction in deoxyhemoglobin 
because the increase in blood flow occurs without an increase of similar magnitude in 
oxygen extraction (Roy & Sherrington, 1890; Fox & Raichle, 1985). Since deoxyhemoglobin is 
paramagnetic, it alters the T2  weighted magnetic resonance image signal (Ogawa et al, 
1990). Thus, deoxyhemoglobin is sometimes referred to as an endogenous contrast 
enhancing agent, and serves as the source of the signal for fMRI. Using an appropriate 
imaging sequence, human cortical functions can be observed without the use of exogenous 
contrast enhancing agents on a clinical strength (1.5 T) scanner (Bandettini et al., 1992, 1993; 
Kwong, et al, 1992; and Turner, et al, 1993; Schneider et al, 1993). Functional activity of the 
brain determined from the magnetic resonance signal has confirmed known anatomically 
distinct processing areas in the visual cortex (Belliveau, et al, 1991; Ogawa, et al, 1992; 
Schneider, et al, 1993), the motor cortex, and Broca's area of speech and language-related 
activities (Hinke et al., 1993; Kim et al., 1995). Further, a rapidly emerging body of literature 
documents corresponding findings between fMRI and conventional electrophysiological 
techniques to localize specific functions of the human brain (Atlas et al., 1996; Puce, et al, 
1995; Burgess, 1995; Detre, et al, 1995; George, et al, 1995; Ives, et al, 1993). Consequently, the 
number of medical and research centers with fMRI capabilities and investigational 
programs continues to escalate.  
The main advantages to fMRI as a technique to image brain activity related to a specific task 
or sensory process include: 
 the signal does not require injections of radioactive isotopes 
 the total scan time required can be very short  
 the in-plane resolution of the functional image is generally about 1.5 x 1.5 mm although 
resolutions less than 1 mm are possible.  
www.intechopen.com
 
Diagnostics and Rehabilitation of Parkinson's Disease 
 
18
The function or dysfunction of the several cortical regions involved in many disease, like 
PD, can be investigated in vivo by means of functional imaging techniques such as fMRI. 
4. Olfactory dysfunction as a early diagnostic marker for Parkinson’s Disease 
Olfactory dysfunction is a frequent non-motor symptom in PD and may be considered as an 
early clinical feature of the disease preceding motor symptoms by years (Ansari & Johnson, 
1975). More than 96% of patients with PD present with olfactory dysfunction, compared 
with an established olfactory loss of at least 25% in the normal population over 52 years of 
age (Haehner et al., 2009). The majority of PD patients are functionally anosmic or severely 
hyposmic. Several studies have demonstrated an absence of correlation between olfactory 
loss and both duration of disease (Doty et al., 1988; Hawkes et al., 1997) and the clinical 
severity of PD (Ramaker et al., 2002), while other studies have found a correlation between 
the severity of PD and certain measures of olfactory function, such as latencies of olfactory 
event-related potentials (OERPs) (Hummel, 1999) and results from an odor discrimination 
task (Tissingh et al., 2001). 
The cause of hyposmia in PD is not yet fully understood. It has been proposed that the 
develop of inclusion bodies, starting from the medulla oblongata and the anterior olfactory 
nucleus before the involvement of other central nervous structures, constitutes the reason of 
olfactory impairment before the motor symptoms appearance (Braak et al., 2003).  
Moreover olfactory loss in PD is not a primary consequence of damage to the olfactory 
epithelium but rather result from distinct CNS abnormalities (Hummel et al., 2010). Studies 
based on biopsies from the olfactory epithelium did not reveal specific changes in the nasal 
mucosa of PD patients compared to patients who were hyposmic for other reasons (rhinitis, 
smoking or toxic agents). With regard to volumetrics of the olfactory bulb (OB) results 
indicated that there is little or no difference between PD patients with anosmia/hyposmia 
and healthy normosmic controls in terms of OB volume (Huisman et al., 2004; Hummel et 
al., 2010; Müller et al., 2005). Support for these results has come from a study that found an 
increase of (inhibitory) dopaminergic neurons in the OB in PD patients (Huisman et al., 
2004). These findings have been interpreted within the context of a possible compensatory 
mechanism in response to the loss of dopaminergic neurons in the basal ganglia. 
While cardinal motor symptoms in PD are closely related to a severe loss of dopaminergic 
cells in the nigro-striatal pathway, early clinical features such as olfactory impairment are 
more likely to be associated with extranigral pathology. Indeed atrophy in olfactory regions 
of the limbic and paralimbic cortex in early PD patients was found (Wattendorf et al., 2009). 
Moreover fMRI in PD patients indicated altered neuronal activity in the amygdaloid 
complex and hippocampal formation during olfactory stimulation (Takeda et al., 2010; 
Welge-Lüssen et al., 2009; Westermann et al., 2008). In addition, neuronal activity in 
components of cortico-striatal loops appears to be up-regulated indicating compensatory 
processes involving the dopaminergic system (Westermann et al., 2008).  
Changes in olfactory function can also be observed using electrophysiological techniques 
such as recording OERPs (Kobal & Pattig, 1978). OERPs are the result of the sequential 
activation of numerous brain areas, starting with amygdala and regions of medial temporal 
lobe followed by the mid-orbito-frontal cortex and insular cortex, along with regions of the 
temporal lobe (Kettenmann et al., 1997). In PD patients OERPs are typically strongly 
delayed or even absent (Hawkes et al., 1999). 
www.intechopen.com
 
Early Marker for the Diagnosis of Parkinson's Disease 
 
19 
In a study combining fMRI and OERPs analysis in patients with PD, non-detectable OERPs 
patients exhibited reduced activity in the anterior cingulate gyrus and portions of the left 
striatum, while detectable ERP patients exhibited higher activation, especially in the 
amygdala, parahippocampal cortex, inferior frontal gyrus, insula, cingulate gyrus, striatum, 
and inferior temporal gyrus. The relationship between the expression of olfactory ERPs and 
cortical activation patterns seen during olfactory stimulation in fMRI in PD patients 
supports the idea that OERPs are a sensitive marker of neurodegeneration in olfactory 
regions, independent of the typically observed nigro-striatal degeneration in PD (Welge-
Lüssen et al., 2009).  
Olfactory dysfunction is more common in PD compared to atypical parkinsonian 
syndromes like PSP or MSA (Doty, 1991, 1993; Wenning et al., 1995). In a study including 37 
patients with PD (Hoehn and Yahr I to IV) and 13 patients with MSA, CBD or PSP, 86 % of 
PD patients showed diminished sense of smell, or severe hyposmia, and 14 % were found to 
have moderate hyposmia, whereas 70 % of the patients with atypical  parkinsonian 
syndromes exhibited moderate to mild hyposmia and 30 % normosmia (Muller et al., 2002). 
Olfactory testing may be an additive, helpful and inexpensive diagnostic instrument to 
support the discrimination of PD from healthy subjects and atypical parkinsonian 
syndromes, before onset of motor symptoms. 
For the clinical assessment of olfactory function, several validated psychophysical tests exist. 
The best-validated olfactory tests include the University of Pennsylvania Smell 
Identification Test, the Connecticut Chemosensory Clinical Research Center Test and the 
Sniffin’ Sticks Test (Cain et al., 1988; Doty et al., 1984; Hummel, 1997, 2007; Kobal et al., 
2000). The Sniffin’ Sticks is based on pen-like odor dispensing devices. It consists of three 
tests namely for odor threshold, discrimination and identification, the sum of which is 
defined as “TDI score”. This score can give an indication of patient’s olfactory performance 
(normosmia: TDI≥30.5, hyposmia: TDI≤30.5, functional anosmia: TDI≤16.5).  
A useful help for the clinical diagnosis of olfactory deficits is represented by system using 
human electro-physiological methods such as OERPs that requests an adequate methods to 
produce a selective and controlled stimulation of the olfactory system. 
Based on the principles of air-dilution olfactometry, Kobal and Platting introduced a 
chemosensory stimulation with stimuli having a rectangular shape with rapid onset, 
precisely controlled in terms of timing, duration, intensity, not simultaneously activating 
other sensory systems (Kobal & Platting, 1978). This can be achieved by the olfactometer 
which is a complex instrument for creation of well defined, reproducible smell or pain 
stimuli in the nose without tactile or thermal stimulation. 
In conclusion the detection of early olfactory dysfunction, less frequent in other form of 
parkinsonism, can be used to assess risk for developing PD in asymptomatic subjects. 
5. Conclusions 
The defining features of PD are characterized by their insidious onset and inexorable but 
variable progression. Reliable and well validated early markers for PD to identify 
individuals “at risk” before motor and non motor symptoms, accurately diagnose 
individuals at the threshold of clinical PD, and monitor PD progression throughout its 
course would dramatically improve patient care and accelerate research into both PD cause 
and therapeutics. During the past two decades, much progress has been made in identifying 
and assessing PD markers, but as yet, no fully validated marker for PD is available. 
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Nonetheless, there is increasing evidence that POM evaluation and advanced in vivo brain 
imaging will provide critical clues to assist in the early diagnosis and medical management 
of PD patients. 
These methods are broadly defined as characteristics that are objectively measured and 
evaluated as indicators of normal biological processes, pathogenic processes, or 
pharmacological responses to a therapeutic intervention. 
The lack of success of recent disease-modifying therapeutic trials coupled with the huge 
expense of other methods, such as  the nuclear medicine, has highlighted the need for such 
an ambitious approach to identify and validate early markers of PD progression for future 
clinical studies of disease-modifying drugs. 
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